RU94017352A - Method of treatment of oncological patients after gastroenteric surgery - Google Patents

Method of treatment of oncological patients after gastroenteric surgery

Info

Publication number
RU94017352A
RU94017352A RU94017352/14A RU94017352A RU94017352A RU 94017352 A RU94017352 A RU 94017352A RU 94017352/14 A RU94017352/14 A RU 94017352/14A RU 94017352 A RU94017352 A RU 94017352A RU 94017352 A RU94017352 A RU 94017352A
Authority
RU
Russia
Prior art keywords
enriched
treatment
nutrient
surgery
gastroenteric
Prior art date
Application number
RU94017352/14A
Other languages
Russian (ru)
Inventor
А.П. Эттингер
Л.Н. Костюченко
С.Р. Лукава
А.Б. Капитанов
Original Assignee
Товарищество с ограниченной ответственностью "Инвест"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Товарищество с ограниченной ответственностью "Инвест" filed Critical Товарищество с ограниченной ответственностью "Инвест"
Priority to RU94017352/14A priority Critical patent/RU94017352A/en
Publication of RU94017352A publication Critical patent/RU94017352A/en

Links

Abstract

FIELD: medicine, oncology. SUBSTANCE: method involves the use of nutrient solutions enriched with proteolytic enzyme preparations. Additionally, nutrient mixtures can be enriched with carotinoid licopin. Nutrient solutions based on standard nutrient mixtures were administrated by intragastral gavage. EFFECT: enhanced effectiveness of treatment, decreased normalization period.

Claims (1)

Изобретение относится к области медицины и касается методов лечения онкологических больных, перенесших операцию на желудочно-кишечном тракте. Цель изобретения - сокращение сроков нормализации пищеварительной функции у онкологических больных, оперированных на желудочно-кишечном тракте. Поставленная цель достигается за счет того, что при внутрижелудочном зондовом питании пациентов питательными растворами на основе стандартных питательных смесей используют питательные растворы, обогащенные препаратами протеолитических ферментов. Дополнительно питательные смеси могут быть обогащены каротиноидом ликопином.The invention relates to medicine and relates to methods for treating cancer patients who underwent surgery on the gastrointestinal tract. The purpose of the invention is to reduce the normalization of digestive function in cancer patients operated on in the gastrointestinal tract. This goal is achieved due to the fact that with intragastric tube feeding of patients with nutrient solutions based on standard nutrient mixtures, nutrient solutions enriched with preparations of proteolytic enzymes are used. Additionally, the nutritional mixtures can be enriched with a carotenoid lycopene.
RU94017352/14A 1994-05-11 1994-05-11 Method of treatment of oncological patients after gastroenteric surgery RU94017352A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU94017352/14A RU94017352A (en) 1994-05-11 1994-05-11 Method of treatment of oncological patients after gastroenteric surgery

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU94017352/14A RU94017352A (en) 1994-05-11 1994-05-11 Method of treatment of oncological patients after gastroenteric surgery

Publications (1)

Publication Number Publication Date
RU94017352A true RU94017352A (en) 1996-07-27

Family

ID=48447626

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94017352/14A RU94017352A (en) 1994-05-11 1994-05-11 Method of treatment of oncological patients after gastroenteric surgery

Country Status (1)

Country Link
RU (1) RU94017352A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2651458C2 (en) * 2013-03-15 2018-04-19 Апталис Фарма Лтд. Composition containing digestive enzymes and nutrients suitable for enteral administration
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
US10206882B2 (en) 2007-02-20 2019-02-19 Allergan Pharmaceuticals International Limited Stable digestive enzyme compositions
US10993996B2 (en) 2013-08-09 2021-05-04 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
US11364205B2 (en) 2010-10-01 2022-06-21 Societe Des Produits Nestle S.A. Stable low digestive enzyme content formulation

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206882B2 (en) 2007-02-20 2019-02-19 Allergan Pharmaceuticals International Limited Stable digestive enzyme compositions
US11364205B2 (en) 2010-10-01 2022-06-21 Societe Des Produits Nestle S.A. Stable low digestive enzyme content formulation
RU2651458C2 (en) * 2013-03-15 2018-04-19 Апталис Фарма Лтд. Composition containing digestive enzymes and nutrients suitable for enteral administration
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
US10993996B2 (en) 2013-08-09 2021-05-04 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration

Similar Documents

Publication Publication Date Title
CY1105818T1 (en) USES OF ET743 IN THE THERAPEUTIC TREATMENT OF CANCER
EP0696456A3 (en) Combination of necrosis inducing substances with substances which are activated by necrosis for the selective treatment of tumours and or inflammatory diseases
PL335370A1 (en) Orally administered preparation for preventing and treating bacterial infections caused by helicobacter sp.
AU2002352187A1 (en) Use of laminarin in the treatment of cancer as well as bacterial, viral and fungal infections
EP1706423B8 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
TNSN04217A1 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
RU94017352A (en) Method of treatment of oncological patients after gastroenteric surgery
NO20016004D0 (en) Composition comprising alkaline sphingomyelinase for use as a dietary, nutritional supplement or pharmaceutical product
AU1976183A (en) N-(2-amino-3,5-dibromobenzyl)- trans-4-amino-cyclohexanol derivatives
DE3764532D1 (en) PRODUCT FOR RADIOSENSIBILIZATION OF BIOLOGICAL TISSUES IN RADIOTHERAPY.
WO2004010934A3 (en) Methods for the use of neurotoxin in the treatment of urologic disorders
ATE269065T1 (en) TREATMENT OF DIGESTIVE DISORDERS
PH23658A (en) Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor
RU95104771A (en) Method of treating exacerbating chronic parodontites
NO20020751L (en) Chemically stabilized chlorite solutions for the treatment of cancer and other diseases
RU2149041C1 (en) Method for rendering rehabilitative services to patients radically operated on the occasion of stomach carcinoma and possessing postresection disorders
RU94039944A (en) Acid-milk product for treating allergy
SU1183116A1 (en) Method of treatment of insufficiency of cholesecretion
RU94041253A (en) Method for treating combined allergic lesions of skin and gastrointestinal tract in children
RU94022334A (en) Method of treatment and prophylaxis of invasion diseases
UA43117A (en) method for treatment of inflammatory diseases of prostate
RU94036142A (en) Method of tumor treatment
RU94039553A (en) Agent for chronic prostatitis treatment
UA30769C2 (en) METHOD OF TREATMENT OF ONCOLOGICAL DISEASES
UA31004A (en) METHOD OF PREVENTION AND TREATMENT OF NEPHROLYTHIA